Review Article

Efficacy of Memantine, Donepezil, or Their Association in Moderate-Severe Alzheimer’s Disease: A Review of Clinical Trials

Table 2

Assessment scales mainly used in the clinical trials reviewed.

Scale acronym Definition Description

ADAS-Cog Alzheimer’s Disease Assessment Scale Cognitive SubscaleStandard instrument for measuring cognitive ability on an 11-item scale in patients with mild-to-moderate disease. Scores range from 0 to 70, with higher scores indicating higher impairment

ADCS-ADL Alzheimer’s Disease Cooperative Study- Activities for Daily LivingAssessment of functional abilities on a 19-item, 54-point scale modified for moderate-to-severe dementia (a 23-item scale is used for mild-to-moderate disease subjects). A higher score indicates better functioning

CIBIC-plus Clinician’s Interview-Based Impression of Change plusCaregiver input evaluates overall global change relative to the baseline level in cognitive, functional, and behavioural aspects. The scale ranges from 1 (very much improved) to 7 (very much worsened)

FAST Functional Assessment StagingEvaluates dementia progression from stage 1 (normal) to 7 (severe dementia)

GDS Global Deterioration ScaleEvaluates overall cognitive and functional capacity on a 7-stage scale, based on the patient and caregiver assessment. Higher stages indicate greater impairment

MMSE Mini-Mental State ExaminationEvaluates the cognitive function on a 30-point scale. A higher score indicates a better function

NPINeuropsychiatric InventoryCaregiver-rated assessment that evaluates the patient’s behaviour on a 12-item, 144-point scale. A lower score indicates a better behavior

SIBSevere Impairment BatteryEvaluates the cognitive dysfunction on a 40-item, 100-point scale in patients with moderate-to-severe Alzheimer’s disease. A higher score indicates better cognitive functioning